The successful use of tocilizumab as third-line biologic therapy in a case of refractory anti-synthetase syndrome

Murphy, SM, Lilleker, JB, Helliwell, P et al. (1 more author) (2016) The successful use of tocilizumab as third-line biologic therapy in a case of refractory anti-synthetase syndrome. Rheumatology, 55 (12). pp. 2277-2278. ISSN 1462-0324

Metadata

Authors/Creators:
  • Murphy, SM
  • Lilleker, JB
  • Helliwell, P
  • Chinoy, H
Dates:
  • Published (online): 21 August 2016
  • Published: 1 December 2016
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 11 May 2018 11:04
Last Modified: 11 May 2018 11:04
Status: Published
Publisher: Oxford University Press
Identification Number: https://doi.org/10.1093/rheumatology/kew296
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Share / Export

Statistics